Ono and Captor collaborate in neurodegenerative diseases

15 November 2022
neuroscience_cns_brain_large

Japanese drugmaker Ono Pharmaceutical (TYO: 4528) and Poland’s Captor Therapeutics (WSE: CTX), a specialist in the development of targeted protein degradation (TPD)-based drugs, have entered a worldwide drug discovery collaboration.

The deal will see the companies link up to develop novel small molecule degrader drugs against a currently undrugged target of interest in neurodegenerative diseases.

"A testament to the promise of our discovery platform and the achievements of our R&D team as they advance our own degrader drug candidates towards the clinic"

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical